aTyr Pharma (NASDAQ: LIFE) is one of 199 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare aTyr Pharma to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.
This table compares aTyr Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|aTyr Pharma Competitors||-3,961.77%||-118.02%||-43.71%|
This is a summary of current ratings and target prices for aTyr Pharma and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|aTyr Pharma Competitors||483||2286||6246||120||2.66|
aTyr Pharma presently has a consensus target price of $4.46, suggesting a potential downside of 7.03%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.74%. Given aTyr Pharma’s competitors stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares aTyr Pharma and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|aTyr Pharma||N/A||-$50.67 million||-2.20|
|aTyr Pharma Competitors||$206.18 million||-$2.14 million||2.50|
aTyr Pharma’s competitors have higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
46.6% of aTyr Pharma shares are owned by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 33.3% of aTyr Pharma shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
aTyr Pharma has a beta of 4.04, suggesting that its share price is 304% more volatile than the S&P 500. Comparatively, aTyr Pharma’s competitors have a beta of 1.62, suggesting that their average share price is 62% more volatile than the S&P 500.
aTyr Pharma competitors beat aTyr Pharma on 8 of the 12 factors compared.
About aTyr Pharma
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.